Hiroto Ohguchi

3.0k total citations
50 papers, 1.1k citations indexed

About

Hiroto Ohguchi is a scholar working on Molecular Biology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Hiroto Ohguchi has authored 50 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 32 papers in Hematology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Hiroto Ohguchi's work include Multiple Myeloma Research and Treatments (27 papers), Protein Degradation and Inhibitors (16 papers) and Histone Deacetylase Inhibitors Research (12 papers). Hiroto Ohguchi is often cited by papers focused on Multiple Myeloma Research and Treatments (27 papers), Protein Degradation and Inhibitors (16 papers) and Histone Deacetylase Inhibitors Research (12 papers). Hiroto Ohguchi collaborates with scholars based in Japan, United States and Singapore. Hiroto Ohguchi's co-authors include Teru Hideshima, Kenneth C. Anderson, Paul G. Richardson, Güllü Görgün, Naoya Mimura, Francesca Cottini, Nikhil C. Munshi, Rikio Suzuki, Diana Cirstea and Takeshi Harada and has published in prestigious journals such as Nature Communications, Blood and PLoS ONE.

In The Last Decade

Hiroto Ohguchi

46 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroto Ohguchi Japan 19 768 367 276 125 107 50 1.1k
Jay Yang United States 18 810 1.1× 318 0.9× 281 1.0× 85 0.7× 84 0.8× 103 1.3k
Olga Goloubeva United States 16 755 1.0× 264 0.7× 502 1.8× 174 1.4× 48 0.4× 27 1.3k
Masamichi Mori Japan 17 524 0.7× 249 0.7× 407 1.5× 189 1.5× 93 0.9× 41 1.1k
Donald J. Johann United States 18 805 1.0× 161 0.4× 389 1.4× 126 1.0× 102 1.0× 59 1.4k
Pascale Lejeune Germany 16 876 1.1× 287 0.8× 522 1.9× 149 1.2× 44 0.4× 44 1.6k
B Soehnlen United States 11 582 0.8× 269 0.7× 513 1.9× 125 1.0× 64 0.6× 15 1.2k
Monica M. Olcina United Kingdom 18 904 1.2× 96 0.3× 648 2.3× 234 1.9× 31 0.3× 30 1.5k
Patrick Maier Germany 16 417 0.5× 57 0.2× 263 1.0× 111 0.9× 25 0.2× 31 889
Jae Lee United States 17 450 0.6× 166 0.5× 104 0.4× 78 0.6× 13 0.1× 33 1.1k
B A Teicher United States 11 588 0.8× 136 0.4× 407 1.5× 43 0.3× 49 0.5× 11 902

Countries citing papers authored by Hiroto Ohguchi

Since Specialization
Citations

This map shows the geographic impact of Hiroto Ohguchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroto Ohguchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroto Ohguchi more than expected).

Fields of papers citing papers by Hiroto Ohguchi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroto Ohguchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroto Ohguchi. The network helps show where Hiroto Ohguchi may publish in the future.

Co-authorship network of co-authors of Hiroto Ohguchi

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroto Ohguchi. A scholar is included among the top collaborators of Hiroto Ohguchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroto Ohguchi. Hiroto Ohguchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ohguchi, Hiroto, Sho Kubota, Shingo Usuki, et al.. (2024). Multiple myeloma–associated DIS3 gene is essential for hematopoiesis, but loss of DIS3 is insufficient for myelomagenesis. PubMed. 1(1). 100005–100005.
3.
Zhou, Yue, Nobuaki Kono, Shojiro Kitajima, et al.. (2024). Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells. iScience. 27(12). 111399–111399.
4.
Matsuo, Misaki, Shingo Usuki, Kei-ichiro Yasunaga, et al.. (2024). FOXO1 stimulates tip cell-enriched gene expression in endothelial cells. iScience. 27(3). 109161–109161. 8 indexed citations
5.
Ohguchi, Hiroto, et al.. (2023). DIS3: The Enigmatic Gene in Multiple Myeloma. International Journal of Molecular Sciences. 24(4). 4079–4079. 7 indexed citations
6.
Ohguchi, Hiroto, Teru Hideshima, & Kenneth C. Anderson. (2018). The biological significance of histone modifiers in multiple myeloma: clinical applications. Blood Cancer Journal. 8(9). 83–83. 30 indexed citations
7.
Sagawa, M., Hiroto Ohguchi, Takeshi Harada, et al.. (2017). Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma. Clinical Cancer Research. 23(17). 5225–5237. 30 indexed citations
8.
Ohguchi, Hiroto, Takeshi Harada, M. Sagawa, et al.. (2017). KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival. Leukemia. 31(12). 2661–2669. 68 indexed citations
9.
Ohguchi, Hiroto, Teru Hideshima, Manoj Bhasin, et al.. (2016). The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival. Nature Communications. 7(1). 10258–10258. 75 indexed citations
10.
Suzuki, Rikio, Shohei Kikuchi, Takeshi Harada, et al.. (2015). Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS ONE. 10(12). e0143847–e0143847. 19 indexed citations
11.
Hideshima, Teru, Francesca Cottini, Hiroto Ohguchi, et al.. (2015). Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. Blood Cancer Journal. 5(5). e312–e312. 53 indexed citations
12.
Cirstea, Diana, Loredana Santo, Teru Hideshima, et al.. (2014). Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma. Molecular Cancer Therapeutics. 13(11). 2489–2500. 24 indexed citations
13.
Mimura, Naoya, Teru Hideshima, Toshiyasu Shimomura, et al.. (2014). Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition. Cancer Research. 74(16). 4458–4469. 66 indexed citations
14.
Cirstea, Diana, Teru Hideshima, Loredana Santo, et al.. (2013). Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 27(12). 2366–2375. 47 indexed citations
15.
Suzuki, Rikio, Ralph Mazitschek, Güllü Görgün, et al.. (2013). Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia. 28(3). 680–689. 131 indexed citations
16.
Fabre, Claire, Naoya Mimura, Kathryn Bobb, et al.. (2012). Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. Clinical Cancer Research. 18(17). 4669–4681. 66 indexed citations
17.
Onishi, Yasushi, Osamu Sasaki, Satoshi Ichikawa, et al.. (2011). Favorable Outcome of Unrelated Cord Blood Transplantation for Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation. 17(7). 1093–1097. 11 indexed citations
18.
Abe, Masahiro, Hisayuki Yokoyama, Yoko Okitsu, et al.. (2009). Plasma Cell Leukemia Maintaining Complete Remission by Syngeneic Stem Cell Transplantation Combined with Low-Dose Thalidomide Maintenance Therapy. Internal Medicine. 48(20). 1833–1835. 3 indexed citations
19.
Ohguchi, Hiroto, Toshiya Tanaka, Aoi Uchida, et al.. (2008). Hepatocyte Nuclear Factor 4α Contributes to Thyroid Hormone Homeostasis by Cooperatively Regulating the Type 1 Iodothyronine Deiodinase Gene with GATA4 and Krüppel-Like Transcription Factor 9. Molecular and Cellular Biology. 28(12). 3917–3931. 36 indexed citations
20.
Miyamura, Koichi, Tohru Fujiwara, Yoko Okitsu, et al.. (2008). Myeloablative Cord Blood Transplantation for Adults With Hematological Malignancies Using Tacrolimus and Short-Term Methotrexate for Graft-Versus-Host Disease Prophylaxis: Single-Institution Analysis. Transplantation Proceedings. 40(10). 3637–3642. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jay Yang Breakdown of academic impact, for papers by Olga Goloubeva Breakdown of academic impact, for papers by Masamichi Mori Breakdown of academic impact, for papers by Donald J. Johann Breakdown of academic impact, for papers by Pascale Lejeune Breakdown of academic impact, for papers by B Soehnlen Breakdown of academic impact, for papers by Monica M. Olcina Breakdown of academic impact, for papers by Patrick Maier Breakdown of academic impact, for papers by Jae Lee Breakdown of academic impact, for papers by B A Teicher
Rankless by CCL
2026